Financial Times US Pharma and Biotech Summit

29 – 30 September 2020, virtual event

Critical issues set to re-shape the sector in the wake of the COVID-19 pandemic

The Financial Times US Pharma and Biotech Summit brings together industry leaders and experts to share insights and perspectives on the critical issues set to re-shape the sector in the wake of the COVID-19 pandemic.

**This event is now closed** - please see details for the upcoming FT Global Pharmaceutical & Biotech Summit (9-11 Nov)

Featured speakers include:

Robert Bradway, Chairman and CEO, Amgen

Alexander Hardy, CEO, Genentech

Leonard Schleifer, Co-Founder, President and CEO, Regeneron

Stéphane Bancel, CEO, Moderna

Stephen M. Hahn, Commissioner, U.S. Food & Drug Administration (FDA)

Joanne Waldstreicher, Chief Medical Officer, Johnson & Johnson

Husseini Manji, Global Head, J&J Science for Minds, Johnson & Johnson

Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi

Jessica Mega, Chief Medical & Scientific Officer, Verily

Cristina Ortega Duran, Chief Digital Health Officer R&D, AstraZeneca

Kim Branson, Senior Vice President, Global Head of AI and Machine Learning, GSK

Rich Carter, VP, Chief Digital Officer, Eli Lilly & Company

ICON speakers:

Mr. George A. McMillan, ICON Chief Commercial Officer

Mr. George McMillan

Chief Commercial Officer, ICON plc

29 September

2:30pm - 2:55pm EST

Fireside chat
: 'Post COVID market and drug development dynamics'. Interviewed by Sarah Neville, Global Pharmaceuticals Editor, Financial Times 


Andrew Garrett

Andrew Garrett

Executive Vice President of Scientific Operations, ICON plc

30 September

12:40pm -1:25pm EST

Panel: Accelerating Drug Development to Save Time, Money and Lives

The coronavirus crisis has publicly exposed the difficulties of developing drugs quickly when needed. Now is the time to look at how product development processes can be made faster and more dynamic without losing trust. Technology surely has a big role to play but so do regulators, policymakers and patients.      

  • How could AI be used to support drug discovery and decision-making in a time of crisis?
  • Where have processes being accelerated or bypassed in the quest to develop a vaccine for Covid-19?
  • How are data applications making clinical trials cheaper, faster and more representative?
  • What regulatory reforms could be considered to support faster product development without lowering standards?
  • What is the case against changing standards of how drugs are developed and approved?

Andy Garrett, Executive Vice President, Scientific Operations, ICON

Kim Branson, Global Head of AI and Machine Learning, GSK

Cristina Ortega Duran, Chief Digital Health Officer, R&D, AstraZeneca

Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

Cynthia Dukes, PA-C, MT - VP, DDS, Vaccines, Infectious Disease, ICON plc

Cynthia Dukes, PA-C, MT

VP, Drug Development Services and Global Head of Vaccine Center of Excellence, ICON plc

30 September

1:40pm -2:40pm EST

Roundtable: The Hunt for a Covid-19 Vaccine - Mapping the Critical Success Factors for Clinical Trial Success

Moderator: Cynthia Dukes

The hunt for a coronavirus vaccine is intensifying, and developers are facing an unprecedented level of scrutiny as they move their vaccine candidates into the crucial Phase 3 clinical trials – the longest, most expensive and high-stakes part of the process. Time is of the essence, leaving little margin for error, but developers must grapple with a range of hurdles and uncertainties before their much-anticipated products can make the leap from the lab to patients : they must design and conduct late-stage clinical trials in conditions of a pandemic, and in a way that allows them to demonstrate the full efficacy of their candidates, and they must meet the regulators’ evolving guidelines for the conduct of Covid-19 clinical trials and their needs for high-quality data. Success in these endeavours brings not only commercial opportunities, but the value that comes from enhanced reputation.

  • What are the critical success factors to keep for covid-19 clinical trials running at optimal speed and efficiency?
  • How are regulatory guidelines and risk-benefit thinking evolving?
  • What have been the insights and learnings from those already conducting late-stage Covid-19 clinical trials?